Dr. Fish is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
269-01 76th Avenue
New Hyde Park, NY 11040Phone+1 718-470-3460Fax+1 718-343-4642
Summary
- Dr. Jonathan Fish, MD is based in New Hyde Park, NY and specializes in Pediatric Hematology & Oncology. He completed his Pediatric Hematology/Oncology fellowship at the Children's Hospital of Philadelphia, and served his residency in Pediatrics at the Schneider Children's Hospital. Dr. Fish currently serves as Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. His areas of expertise include stem cell transplantation and cellular therapy, leukemia, and gene therapy. He has made significant contributions to medical literature with multiple publications and has participated in clinical trials primarily as a contact or principal investigator. Over his career, he has received several awards, including the Young Investigator Award from the American Society of Pediatric Hematology Oncology and the Young Alumnus Award from Upstate Medical University.
Education & Training
- Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2004 - 2007
- Zucker School of Medicine at Hofstra/Northwell at Cohen Children's Medical CenterResidency, Pediatrics, 2000 - 2003
- SUNY Upstate Medical UniversityClass of 2000
- The University of Western OntarioB.S., With distinction, 1996
Certifications & Licensure
- NY State Medical License 2003 - 2025
- PA State Medical License 2004 - 2008
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- President’s Award Nominee NSLIJ health system, 2013
- Aflac ‘duck print’ Award Recipient 2013
- Young Investigator Award American Society of Pediatric Hematology Oncology, 2008
- Join now to see all
Clinical Trials
- Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Start of enrollment: 2014 Mar 05
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Roles: Contact, Principal Investigator
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) Start of enrollment: 2023 Jan 25
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- Craniospinal irradiation and/or intraventricular radioimmunotherapy after high-dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma-Sa...Sameer Farouk Sait, Nancy A Kernan, Elizabeth Klein, Barbara Spitzer, Carolyn Fein Levy
Pediatric Blood & Cancer. 2024-11-01 - Barriers to Receiving Follow-up Care Among Childhood Cancer Survivors.Sharon Bossert, William Borenzweig, Catherine Benedict, Jane E Cerise, Elizabeth J Siembida
Journal of Pediatric Hematology/oncology. 2023-10-01 - 6 citationsCost of survivorship care and adherence to screening-aligning the priorities of health care systems and survivors.Catherine Benedict, Jason J Wang, Marina L. Reppucci, Charles Schleien, Jonathan D. Fish
Translational Behavioral Medicine. 2021-02-11
Journal Articles
- Arterial Stiffness in Childhood Cancer SurvivorsKrystal JI, Reppucci M, Mayr T, Fish JD and Sethna C, Pediatr Blood Cancer, 1/1/2015
- Fertility Preservation for Adolescent Women with CancerFish JD, AMSTARs. Adolesc Med, 1/1/2012
- reproducible method for non-invasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for pre-clinical modelingBarrett DM, Seif AE, Carpentino C, Teachey DT, Fish JD, June CH, Grupp SA, and Reid GS, Blood, 1/1/2011
- Join now to see all
Abstracts/Posters
- PI-103, a dual inhibitor of mTOR and PI3kinase, potentiates rapamycin-mediated ALL cell death and inhibition of proliferationFish JD, Sheen C, Hulitt J, Grupp SA and Brown VI, Pediatric Blood and Cancer; American Society of Pediatric Hematology Oncology Annual Meeting, 1/1/2008
- Targeting of ALL by lentivirus engineered primary human T cellsFish JD, Milone M, Carpenito C, Lakhal M, Ofori E, Danet-Desnoyers G, Riley J, Grupp SA and June C, Pediatric Blood and Cancer; American Society of Pediatric Hematology Oncology Annual Meeting, 1/1/2007
- PI3-Kinase inhibition induces ALL cell death, potentiates rapamycin, and prevents IL-7 mediated resistance to rapamycinFish JD, Sheen C, Bruno M, Hulitt J, Grupp SA and Brown VI, Pediatric Blood and Cancer; American Society of Pediatric Hematology Oncology Annual Meeting, 1/1/2007
- Join now to see all
Lectures
- Arterial Stiffness in Childhood Cancer Survivors1/1/2015
- Costs of Screening of Childhood Cancer Survivors1/1/2015
- Adherence to Screening Recommendations Among Survivors of Childhood Cancer1/1/2015
- Join now to see all
Other
- Bone Marrow Transplantation, Long-Term EffectsFish JD, Raval GG, Mehta P, eMedicine from WebMD
http://emedicine.medscape.com/article/989518-overview
1/16/2009
Press Mentions
- New Data Notes Financial Considerations for How Health Systems Support Childhood Cancer SurvivorsJanuary 8th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: